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Since the first successful birth in 1978 following in vitro fertilisation (IVF), this has
become established treatment for infertility and is available at more than thirty
centres in the United Kingdom. Oocyte donation has extended the use of IVF
technology for conditions where a genetic abnormality exists or where repeated
attempts at IVF have failed to achieve fertilisation. In cases where the ovaries are
absent or have failed prematurely, the procedure can be combined with steroid
replacement therapy to maintain a successful pregnancy. Donated oocytes have
been obtained from relatives and friends, but more recently it has been
recommended that the donor should remain anonymous. The following case
report is of the first such pregnancy achieved in Northern Ireland.
CASE REPORT
A 25-year-old married woman presented to the infertility clinic, Royal Maternity
Hospital, Belfast, in 1986, complaining of secondary amenorrhoea. Investig-
ations had been undertaken at the age of 21 and had revealed elevated serum
gonadotrophins in keeping with a diagnosis of premature ovarian failure. The
chromosome complement was that of a normal female. Hormone replacement
therapy with conjugated oestrogens 0-625mg and norgestrel 0-15mg
(Prempak -C, Ayerst) was commenced. The possibility of pregnancy achieved by
IVF using a donated ovum was discussed, and it was advised that an anonymous
arrangement would be preferable.
The patient remained on hormone replacement therapy until October 1987
when an IVF programme commenced in Northern Ireland. Hormone therapy was
then altered to a maintenance dose of oral oestradiol valerate (Progynova,
Schering) 2mg daily until a potential donor became available. A random serum
oestradiol was 2509 pmol/l on this regimen. The dose was increased to 4mg
daily shortly after a potential donor, who was undergoing gamete intrafallopian
transfer (GIFT) had commenced superovulation therapy. Eight oocytes were
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obtained from the donor by laparoscopy, four of which were replaced in her
fallopian tubes with capacitated spermatozoa from her husband.
The remaining four oocytes were transferred to prepared culture dishes contain-
ing Earle's balanced salt solution with 10% human serum. A sample of the
recipient's husband's semen was prepared by a centrifugation and swim-up
technique, which enables the motile sperm to be extracted. Four hours later
100,000 sperm were added to each of the dishes containing an individual
oocyte, and after 18 hours three oocytes had developed two pronuclei, which
confirmed that fertilisation had occurred. At this time the patient was asked to
increase her oestradiol valerate to 6mg daily and was also given progesterone
50mg (Gestone, Paines & Byrne) by intramuscular injection. This was repeated
the following day tocoincide with embryo transfer, at which time serum oestradiol
was 2591 pmol/l and progesterone was 32-2 nmol/l, both of these levels being
within the normal range.
Forty-eight hours after insemination two of the three embryos had divided
normally. Embryo transfer was carried out under aseptic conditions, with the
patient in the lithotomy position, using a fine plastic catheter which was inserted
through the cervical os. The two embryos were placed in the recipient's uterus in
3 p1 of medium with the added human serum concentration increased to 75%.
Hormone maintenance therapy was provided by oestradiol valerate 4mg and
progesterone 50mg daily, and the serum levels of these two hormones checked
twice weekly; all values initially followed the normal curve.'
Fifteen days after embryo transfer a pregnancy test was positive, and at 40 days a
fetal circulation was identified with ultrasound. During the fourth week of
pregnancy the progesterone levels fell below the optimal range (Figure), so the
dose of progesterone was increased to 100mg daily. At six and eight weeks the
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serum progesterone again fell below normal and further supplements were given
in the form of vaginal pessaries (Cyclogest, Hoechst) with the dose increasing
from 400mg daily at six weeks to 1200mg by nine weeks. Oestradiol levels
remained well above the suggested range.2
At 10 weeks' gestation, both oral oestradiol and the systemic progesterone
therapy were withdrawn, and one week later the progesterone pessaries were
stopped. At this stage serum oestradiol and progesterone were 11,720 pmol/l
and 153' 5 nmol/I respectively. The levels dropped sharply after withdrawal of
the replacement therapy, then over the next two weeks gradually returned
towards the normal range for pregnancy. Serial ultrasonic scansshowed a healthy
single fetus.
The remainder of the pregnancy progressed satisfactorily until 32 weeks'
gestation, when the patient was admitted with a painful antepartum
haemorrhage. A-diagnosis of placental abruption was made and delivery was
carried out by Caesarian section, resulting ina live female infant weighing 1710g.
Streak ovaries with no evidence of corpus luteum formation were noted.
The baby required minimal special care and was discharged aged 27 days,
weighing 2230g. The mother had no postnatal complications. Measurement of
serum oestradiol and progesterone levels was continued, and showed a gradual
fall in oestradiol levels and a rise in gonadotrophins. The increase in FSH
preceded that of LH, but by four weeks postpartum both had returned to
postmenopausal levels.
DISCUSSION
Oocyte donation has been used with a high success rate in animal husbandry for
many years.3 In humans, it was not until the technique of IVF had been perfected
that the first pregnancy in a patient with ovarian failure was established.4 There
have, however, been few published accounts of the outcome of pregnancy after
donation of oocytes fertilised in vitro, and the success rate can vary from zero
to 38%.5
Where the recipient has normal menstrual function, synchronisation of donor and
recipient is necessary to aim fortransfer of a four to six cell embryo on day 17-19
of the recipient's cycle. To achieve this it is usual to recruit a designated donor,
such as a woman undergoing laparoscopic sterilisation, who has agreed to
superovulation with gonadotrophins prior to the procedure. This also allows
approximate matching of physical characteristics while preserving anonymity.
Synchronisation can be achieved by adjusting the donor's menstrual cycle using
oral contraceptive pills or norethisterone.6
In patients without ovarian function, a variety of steroid replacement protocols
have been used to mimic the normal menstrual cycle.2'7'8 Although it has been
established that luteal progesterone is necessary to allow implantation and to
maintain pregnancy, the relative importance ofoestradiol is unclear.9 Until further
information is obtained from prospective studies, it seems reasonable to simulate
the menstrual cycle, thus providing suitable endometrium for implantation, and
subsequently to increase steroid therapy to maintain the pregnancy. A positive
13-HCG titre may be obtained as early as 10 days after embryo transfer. If still
negative three weeks after embryo transfer, it is assumed that the patient is not
pregnant, and the oestrogen and progesterone doses are tapered off to allow
menstruation to occur.
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A useful and simple method of preparation of a recipient depends on priming the
endometrium with an adequate oestrogen dosage, then inducing secretory
change in the proliferative endometrium by introduction of progesterone just
prior to recovery of the donated oocytes.'0 Thus, the patient can be maintained
on oestradiol therapy for several weeks and careful synchronisation with a
potential donor is not required, allowing greater flexibility. This regimen is
applicable to both normally cycling recipients and to those with ovarian failure.
A similar protocol was used in this case, with subsequent requirements in
pregnancy determined by twice weekly hormone levels.
Due to the small number of pregnancies achieved in patients with ovarian failure,
no definite guidelines exist for when steroid therapy can be safely withdrawn.
Csapo et al showed that the shift from ovarian to placental maintenance of
pregnancy occurred at around 50 -60 days' gestation.11 Lutjen et al, in their first
reported case,4 withdrew oestradiol therapy at 72 days' gestation. Progesterone
withdrawal was attempted from days 63-73, but was reintroduced when serum
levels fell, and maintained until day 133. In this case report, serum levels also fell
following sequential withdrawal of the progesterone supplements, but there was
evidence of an active fetus on ultrasound scanning. Therefore, it was decided to
await events and, indeed, progesterone levels returned to normal over the next
two weeks. Very early withdrawal of oestradiol at 35 days and of progesterone at
48 days has been reported, with a successful pregnancy.'2
With the simplified form ofsteroidal therapy described above, donors assigned in
advance are not essential, and use can be made of excess oocytes from
consenting patients in a GIFT or IVF programme. This avoids any added risk to a
donor from either the gonadotrophin therapy or the oocyte recovery techniques,
but the oocytes do however tend to be sub-optimal because those with the best
morphology are reserved for the donor. Consenting women undergoing laparo.
scopic sterilisation should prove to be another acceptable source of donor
oocytes, as the potential extra risks are minimal and their fertility has been
proven.
Donation of oocytes from friends or relatives of the recipient couple has been
used, and has been accepted by the Waller Committee in Australia.'3 However,
as the child will be known to the donor, there is the possibility of social and
psychological problems arising between donor and recipient, to the detriment of
the child. Anonymous donors are therefore preferable, and this is recommended
by the Voluntary Licensing Authority in the United Kingdom'4 and the American
Fertility Society.'5
CONCLUSION
Oocyte donation has extended the uses of IVF to enable women previously
considered irreversibly infertile, or carrying abnormal genes, to achieve a
pregnancy. It can also provide a human model for the assessment of the relative
roles of oestrogen and progesterone in the luteal phase and in early pregnancy.
This case report outlines the first successful pregnancy in Northern Ireland
following anonymous ovum donation and in vitro fertilisation. This was also the
first pregnancy achieved in the IVF programme, with the first embryo transfer
performed: this must be a unique event.
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